Age-related Macular Degeneration Market Size was ~USD 9500 Million in 2022 | DelveInsight

DelveInsight's 'Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034' report deliver an in-depth understanding of the Age-related Macular Degeneration, historical and forecasted epidemiology as well as the Age-related Macular Degeneration market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Key Takeaways from the Age-related Macular Degeneration Market Report

* The expected launch of therapies and the increasing prevalence will lead to market positive growth of Age-related Macular Degeneration (AMD) during the forecast period, 2023-2034.
* As per the assessments made from data presented by various organizations like American Macular Degeneration Foundation (2022), Prevent Blindness (2022), Fort Lauderdale Eye Institute (2022), and others, nearly 85-90% of the cases of macular degeneration are of the "dry"(atrophic) type.
* The US accounted for approximately 17,688,550 Age-related Macular Degeneration prevalent cases in the year 2022.
* The leading Age-related Macular Degeneration Companies working in the market include Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA In, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Novartis, Luxa Biotechnology, Gemini Therapeutics and others.
* Promising Age-related Macular Degeneration Pipeline Therapies in the various stages of development include LHA510 Ophthalmic Suspension, OTX-TKI/Sham, Aflibercept/Sham, CLG561, SB11 (Proposed ranibizumab biosimilar), Lucentis (ranibizumab), ACZ885, Faricimab, and others.
* April 2024: Neuracle Genetics Inc.- A Phase 1/2a Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration.
* April 2024:- LumiThera Inc.- An Open-Label, Prospective, Multi-Center Extension Study to Assess the Long-Term Safety and Efficacy of Photobiomodulation (PBM) in Subjects With Dry Age-Related Macular Degeneration (AMD) (LIGHTSITE IIIB).
* April 2024:- Perceive Biotherapeutics Inc.- VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration. This is a prospective, open-label, multi-center Phase 1/2a study to evaluate the safety of a single, unilateral intravitreal (IVT) injection of three dose levels of VOY-101 therapy in subjects with advanced non-neovascular age-related macular degeneration (AMD).
* April 2024:- Genentech Inc.- A Multicenter, Prospective, Observational Study of the Progression of Intermediate Age-Related Macular Degeneration. This is a multicenter prospective study in participants with intermediate age-related macular degeneration (iAMD). One primary objective of this study is to assess iAMD disease progression, by the timeline and rates of conversion for high-risk iAMD at baseline to more advanced atrophic AMD stages. The other primary objective of this observational study is to assess the feasibility of measuring the rate of photoreceptor loss as a potential clinical endpoint. The study will consist of an observation period of approximately 3 years (~144 weeks) for participants.
* April 2024: Novartis Pharmaceuticals- A 56-week Phase IIIb/IV, Open-label, One-arm Extension Study to Assess the Efficacy and Safety of Brolucizumab 6 mg in a Treat-to-Control Regimen With Maximum Treatment Intervals up to 20 Weeks for the Treatment of Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study.

Discover which therapies are expected to grab the Age-related Macular Degeneration Market Share @ Age-related Macular Degeneration Market Outlook [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Age-related Macular Degeneration Overview

Age-related Macular Degeneration (AMD) is a progressive eye condition that primarily affects the central part of the retina called the macula. The macula is responsible for providing sharp central vision, which is essential for activities such as reading, driving, and recognizing faces..

Age-related Macular Degeneration Epidemiology Insights

The epidemiology section of Age-related Macular Degeneration offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

* Total Prevalent Cases of Age-related Macular Degeneration
* Total Diagnosed Prevalent Cases of Age-related Macular Degeneration
* Type-specific Diagnosed Prevalent Cases of AMD
* Total Age-specific Cases of Wet AMD, and Dry AMD
* Total Diagnosed Dry AMD Cases by Stages
* Total Geographic Atrophy Cases Associated With Dry AMD by Visual Impairment

Download the report to understand which factors are driving Age-related Macular Degeneration Epidemiology trends @ Age-related Macular Degeneration Epidemiological Insights [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Age-related Macular Degeneration Market Insights

AMD is the most common cause of severe loss of eyesight among people aged 50 and older. It affects the central vision and, with it, the ability to see fine details. In AMD, a part of the retina called the macula get damaged. Medication can help reduce the progression of the illness and prevent vision loss. People rarely lose all of their vision from age-related macular degeneration. Their central vision might be bad, but they're still able to do many normal daily activities. Usually, patients are also able to still use their peripheral vision. The dry age-related macular degeneration (dAMD) tends to get worse slowly. There is no cure for macular degeneration. Treatment may slow it down or keep the loss of vision. A large number of studies found have shown, that people with dry AMD could slow the disease by taking supplements of vitamins C and E, lutein, zeaxanthin, zinc, and copper.

Age-related Macular Degeneration Treatment Landscape

The therapeutic landscape of dry AMD is devoid of any approved treatment, and to manage this indication, and there is a substantial unmet need for a therapy to slow its worsening. The pathophysiology of dry AMD is poorly understood. However, there are chances of failure to reach the primary outcomes that might be linked to the advanced stage of the disease rather than a lack of action on appropriate targets. There is a significant unmet need for a therapy to decrease its progression. Dry AMD's pathogenesis is poorly known. On the other hand, failure to achieve the primary outcomes may be due to the advanced stage of the disease rather than a lack of action on appropriate targets.

To know more about Age-related Macular Degeneration treatment guidelines, visit @ Age-related Macular Degeneration Treatment Market Landscape [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Age-related Macular Degeneration Drug Market

The overall market of Age-related Macular Degeneration (AMD) is expected to boost due to rising prevalence cases over the globe and thus the surge in treatment options. Along with the expected launch of emerging therapies, the treatment market of Wet-AMD and Dry-AMD is supposed to boost in the forecasted period (2023-2034).

Age-related Macular Degeneration Emerging Therapy Assessment

Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Market key player, such as Opthea Limited, Kodiak Sciences Inc, Outlook Therapeutics, Inc., and others are developing drugs for the treatment of Wet-AMD, whereas, companies like Alkeus Pharmaceuticals, Iveric Bio, and others are developing drugs for the treatment of Dry-AMD.

Age-related Macular Degeneration Drugs Uptake

* OPT-302 (sVEGFR-3) is the first 'Trap' inhibitor of VEGF-C and VEGF-D designed specifically for the eye being developed by Opthea Limited. OPT-302 blocks the two members of the VEGF family which cause blood vessels to grow and leak. In combination with anti-VEGF-A therapies, OPT-302 completely shuts-down VEGFR-2 and VEGFR-3 activity and targets mechanisms of resistance and suboptimal clinical response to existing therapies. The company is currently conducting two concurrent Phase III clinical trials of OPT-302 for the treatment of wet AMD.
* Kodiak Science's KSI-301 is a novel anti-VEGF biologic designed to rapidly inhibit VEGF and provide extended durability of action to reduce the burden of frequent anti-VEGF injections. Delivering potent and sustained VEGF inhibition enables patient compliance, results in long-term efficacy, and improves visual acuity outcomes. The drug is currently being evaluated in Phase III.
* RGX-314 is being developed by Regenxbio as a novel, one-time Subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. It is a potential one-time gene therapy for the treatment of wet AMD, diabetic retinopathy (DR) and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wAMD in Phase II and II/III and Phase III clinical trials.
* Alkahest is developing AKST4290, an oral drug that inhibits CCR3, a key receptor for eotaxin, to modulate inflammation, immune cell recruitment, and neovascularization. This innovative, twice-daily pill offers convenience and potential benefits for conditions like wet age-related macular degeneration and other neurological and immunological diseases. It is currently in Phase II of clinical development.

Age-related Macular Degeneration Companies

Several Age-related Macular Degeneration companies working in the market include Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA In, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Novartis, Luxa Biotechnology, Gemini Therapeutics and others.

Learn more about the FDA-approved drugs for Age-related Macular Degeneration @ Drugs for Age-related Macular Degeneration Treatment [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Age-related Macular Degeneration Market Report

* Coverage- 7MM
* Age-related Macular Degeneration Companies- Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA In, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Novartis, Luxa Biotechnology, Gemini Therapeutics and others.
* Age-related Macular Degeneration Pipeline Therapies- LHA510 Ophthalmic Suspension, OTX-TKI/Sham, Aflibercept/Sham, CLG561, SB11 (Proposed ranibizumab biosimilar), Lucentis (ranibizumab), ACZ885, Faricimab, and others.
* Age-related Macular Degeneration Market Dynamics: Age-related Macular Degeneration Market Drivers and Barriers
* Age-related Macular Degeneration Market Access and Reimbursement, Unmet Needs, KOL's Views, and Analyst's Views

Discover more about Age-related Macular Degeneration Drugs in development @ Age-related Macular Degeneration Clinical Trials Assessment [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Report Introduction

3. Wet AMD Market Overview at a Glance

4. Dry AMD Market Overview at a Glance

5. Wet AMD Market: Future Perspective

6. Executive Summary

7. Key Events

8. Disease Background and Overview

9. Epidemiology and Patient Population

10. Patient Journey

11. Marketed Drugs

12. Emerging Drugs of Wet AMD

14. AMD: Seven Major Market Analysis

15. Key Opinion Leaders' Views

16. Market Drivers

17. Market Barriers

18. SWOT Analysis

19. Market Access and Reimbursement of Wet AMD

20. Unmet Needs

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=agerelated-macular-degeneration-market-size-was-usd-9500-million-in-2022-delveinsight]
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.